Announcement
SCHOTT Poonawalla Private Limited will officially become SCHOTT Pharma India Private Limited effective 28 October 2026. The press release emphasizes that the name change does not alter ownership, management, employee base, business strategy, operations, product portfolio, or existing customer commitments. The rebranding aligns the Indian entity more closely with the global SCHOTT Pharma network, underscoring its role in delivering high‑quality drug containment and delivery solutions for pharmaceutical and biotech customers.
Operational Continuity and Heritage
The company highlights a heritage of over 140 years in specialty glass and advanced materials, positioning the new identity as a continuation of its long‑standing market expertise in India. It reiterates that the business will maintain its current manufacturing footprint, customer relationships, and market expertise while leveraging SCHOTT Pharma’s global innovation and scientific excellence.
Production Capacity and Pandemic Contribution
SCHOTT Pharma India produces more than 3 billion glass containers each year, a volume that translates to roughly 7,000 injections reaching patients every minute. During the COVID‑19 pandemic, its pharmaceutical vials supported the administration of over 4.3 billion vaccine doses worldwide, including 3 billion doses within India. The firm is identified as India’s sole manufacturer of glass pre‑fillable syringes and sterile formats, reinforcing domestic supply capabilities for critical injectable therapies.
Investment and Expansion Plans
The company states that it continues to invest significantly in expanding manufacturing capacity for pre‑fillable syringes and cartridges. These expansions are intended to meet the growing demand for biologics, biosimilars, GLP‑1‑based treatments, and other advanced injectable therapies. The forward‑looking focus includes broadening capabilities across drug containment and delivery, driving innovation through closer customer collaboration, and enhancing operational excellence and sustainability.
Leadership Comments
Roy Joseph, CEO & Managing Director of SCHOTT Pharma India Private Limited, said the new identity represents the next chapter of the company’s journey, combining its Indian strength with SCHOTT Pharma’s global innovation to deepen collaborations and advance drug containment solutions. Dr. Christian Mias, CEO of SCHOTT Pharma AG & Co. KGaA and major shareholder of SCHOTT Pharma India, noted that the name change reinforces the strategic partnership and confirms SCHOTT’s long‑term commitment to India as a key pharmaceutical hub.
Outlook
The press release concludes that SCHOTT Pharma India will continue to support the evolving needs of pharmaceutical and biotechnology firms, contributing to India’s expanding role in the global pharmaceutical value chain while maintaining its commitment to quality, reliability, and patient outcomes worldwide.